Discover the intricacies of molecular landscapes through quantitative mass spectrometry imaging (QMSI)
Aliri’s proprietary imaging workflows will help you understand localization, quantification, and distribution of drugs at the site of action.
Studying drug efficacy at the site of action gives us valuable and unique insights into:
- Drug bioavailability
- Drug biodistribution
- Targeted tissue exposure
- On-tissue PK/PD
- Monitoring the drug effects through readout biomarkers (metabolites, lipids, genes expression, proteins)
Our QMSI spatial platform uses data analysis to conduct molecular distributions, and artificial intelligence to find patterns and make predictions. This advanced imaging technique allows you to visualize the molecule within tissues, and evaluate how prevalent the drug is within the histological region of interest.
Our high expertise in this area sets us apart from other CROs in pharma/bio industries and positions us as a leader in spatial bioanalysis and biology services.
Check out our infographic to learn more about our unique imaging platforms.
A guide to the advantages and disadvantages of sample preparation for small molecules
Accurate and reliable results in the drug discovery process rely heavily on the pivotal role of sample preparation. By adopting optimized sample preparation techniques, you can significantly improve the quality of your data.
Sample preparation for small molecules involves three primary modes:
- Protein precipitation
- Supported liquid exchange / liquid/liquid extraction
- Solid phase extraction
Our comprehensive guide offers valuable insights associated with preparing small molecule samples for analysis, including advantages and disadvantages of each preparation mode.
Timeline planning tips for importing or exporting biological samples
Missed deadlines in drug development often stem from improper planning and coordination during the import and export of biological samples. Establishing and executing a proper plan for this part of the process can help ensure that your program stays on-track, while avoiding unnecessary stress such as costly delays, lost shipments, etc.
Download this infographic to learn more about this robust process:
- Permits and government agency requirements
- Human vs animal requirements
- Timelines and expectations
- Resources and process planning
QMSI vs. QWBA: evaluating benefits and risks
Knowing when to use Quantitative Mass Spectrometry Imaging (QMSI) instead of Quantitative Whole-Body Autoradiography (QWBA) can make or break a timeline and budget for pharma and biotech companies.
Consider the following key advantages when selecting which technique is right for your drug development program:
QSMI Advantages:
- Label-free quantification of thousands of analytes
- Excellent differentiation among parent drugs, metabolites, and other substances
- Highly specific in quantification by location in tissue
QWBA Advantages:
- Highly precise quantification capabilities, even at low and high limits of detection
- Spatial resolution at the cellular level
- Gold standard technique for the late-stage regulatory distribution studies
Even though QWBA remains the gold standard technique during late stage for regulatory agencies, QMSI is frequently used in support of the autoradiography in certain circumstances.
Further evaluate the benefits and risks associated with each technology.
Buy vs Build: Bioanalytical lab
Buying a bioanalytical lab vs. building one yourself – what do you need to consider?
With so many outsourcing/insourcing options across the drug development workflow, Pharma companies are faced with finding the right partner to fit all the needs of their unique molecule. Here are some criteria to consider:
- Time to Launch: timelines depend on the approach. A built-for-purpose project translates to long timelines due to all the parties involved. You need time to evaluate location, engineers, & architects. Return on investment and risk impact: both are dependent on the number of programs and the diversity of projects. To fully evaluate, you need to build utilization models to analyze and make predictions
- Staffing appropriately: the job market can be challenging to navigate, and it could prove to be challenging to find the right expertise and employees. Be prepared for this process to take time and be costly.
- Day to Day Logistics: there are a wide variety of permits & licenses needed for day-to-day operations. This regulatory environment can be complicated to navigate as you manage the applications, requirements and maintenance required.
If you are interested in learning more about permits & licenses specifically, check out our fact sheet: Guidelines to Importing & Exporting Biological Samples - And much more…
Explore our comprehensive guide that outlines the benefits & risks associated with buying or building a bioanalytical lab and see what choice is best for you.
Top 8 Benefits of Mass Spectrometry Imaging Early in Drug Development
Mass spectrometry imaging (MSI) is a groundbreaking technology that provides visuals of complex biological samples to study a drug’s distribution and understand its potential toxicity. MSI can unlock crucial data and give scientists additional insights into drug discovery, diseases, and personalized medicine.
MSI is beneficial in early development and murine models across many therapeutic areas and is especially suited to oncology due to the availability of tissue. With MSI you can:
- Speed up and optimize the drug discovery process
- Visualize drug distribution in tissues and tissue sub-compartments
- Analyze samples for thousands of compounds at once
- Eliminate sensitivity and chemical alteration concerns
- Know whether efficacy is possible based on distribution
- Locate and identify metabolites to understand potential toxicity
- Improve understanding of pharmacokinetics and pharmacodynamics
- Save money and provide a competitive development edge
Download our infographic to learn more about the benefits of mass spectrometry imaging in oncology.
BIOANALYSIS: Approaches and Techniques for Small vs. Large Molecules
Bioanalysis plays a crucial role in the evaluation of potential drug candidates and in understanding the drug’s pharmacokinetics and pharmacodynamic profile during early clinical trials. By documenting a drug’s behavior within the body, our specialists generate essential data that regulatory authorities rely on to determine whether the drug is safe for market release.
Before choosing a suitable testing technique, it’s important to understand three factors, type of molecule, unique properties of the drug, and its intended application. Regardless of the molecule size, it’s crucial to validate appropriate methods capable of measuring the drug’s concentration and bioactivity over time.
Download our infographic to learn more.
Importing and exporting biological samples: Dos and don’ts
To ensure that your drug program’s timeline stays on track, it is crucial to follow the strict guidelines for importing and exporting biological samples. Too often, there are several mistakes with execution that could have been avoided with proper planning, coordination, and communication. These errors not only lead to frustration but also can result in:
- Costly delays
- Project rework
- Logistic challenges
- Lost, delayed, or damaged samples
- Handling mishaps
Discover the 5 best practices and mistakes to avoid when navigating the import and export of biological samples.
Common Approaches to Bioanalysis of Oligonucleotides
The significance of oligonucleotides (OGNTs) in drug development is increasing rapidly, as they offer promising and life-changing treatments that can improve patients’ lives. However, the promising and vast opportunities of OGNTs come with a unique set of challenges and nuances unlike other types of molecules.
Within bioanalysis, there are 5 main approaches for OGNTs to consider:
- LC/UV
- LC/MS/MS
- Hybridization LF/FD
- LC/HRMS
- Hybridization ELISA
Learn how to evaluate the pros and cons of each approach to decide what’s best for your OGNTs.